Related Experiment Videos
The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective
1Harvard Medical School, Boston, Massachusetts.
Herz
|December 1, 1993
Summary
Angiotensin-converting enzyme (ACE) inhibitors, like captopril, significantly reduce death and cardiovascular events in myocardial infarction survivors with left ventricular dysfunction. This therapy offers improved outcomes for high-risk patients post-heart attack.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial infarction survivors face elevated risks of subsequent cardiovascular events, including heart failure.
- Left ventricular dysfunction is a primary risk factor for adverse outcomes post-myocardial infarction.
- While aspirin and beta-blockers are established therapies, the role of ACE inhibitors in improving outcomes for these patients was under investigation.
Purpose of the Study:
- To evaluate the efficacy of long-term angiotensin-converting enzyme (ACE) inhibition therapy in reducing morbidity and mortality among myocardial infarction survivors.
- To determine if captopril, an ACE inhibitor, improves outcomes in patients with left ventricular dysfunction after myocardial infarction.
Main Methods:
- The Survival and Ventricular Enlargement (SAVE) trial was conducted to assess the impact of long-term ACE inhibition.
- Captopril was administered to patients, and outcomes were compared against a placebo group.
Main Results:
- Captopril therapy resulted in a 19% reduction in all-cause mortality (p=0.019).
- Cardiovascular death was reduced by 21% (p=0.014) and subsequent myocardial infarction by 25% (p=0.012) in the captopril group compared to placebo.
- These risk reductions were observed in patients with left ventricular dysfunction post-myocardial infarction.
Conclusions:
- Angiotensin-converting enzyme (ACE) inhibition with captopril is a proven therapy for extending survival in myocardial infarction survivors.
- Physicians can now incorporate ACE inhibition with captopril into treatment plans for patients experiencing left ventricular dysfunction after a heart attack.